BeyondSpring Inc. — Form 8-K Summary
Report date: September 29, 2026; the principal transaction was entered into September 28, 2026. This current report describes a subsidiary sale and collaboration, and a new at-the-market offering program; it does not report quarterly or annual financial results.
Business context and key transactions
- China trial collaboration and subsidiary sale: BeyondSpring, its majority-owned indirect subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), and Biolin Investment Limited entered into a Share Purchase and Collaboration Agreement. BeyondSpring agreed to sell and transfer to Biolin all issued shares of BeyondSpring Ltd., a wholly owned subsidiary that indirectly holds interests in Bulin.
- Non-cash consideration: Biolin is to conduct and complete the China portion of the DUBLIN-4 global Phase 3 trial of plinabulin plus docetaxel in certain patients with advanced or metastatic non-squamous non-small cell lung cancer. No cash is payable to BeyondSpring at closing.
- Enrollment and potential reversion: Bulin must use commercially reasonable efforts to achieve a patient enrollment target set by BeyondSpring, in its sole discretion, within three years after closing. If the target is missed, Biolin must transfer back a proportional portion of the shares based on the shortfall; if the shortfall is at least 90%, Biolin must return all of the shares.
- Data and licenses: BeyondSpring receives an exclusive, irrevocable, perpetual, non-terminable, sublicensable, transferable, fully paid-up, royalty-free license to use China trial data and information for most purposes, plus a right of reference to relevant data. The parties also grant each other certain freedom-to-operate licenses. BeyondSpring expects the China data to contribute to an integrated global dataset supporting its plinabulin registration strategy.
- ATM program: On September 29, BeyondSpring entered into an agreement with Citizens JMP Securities, LLC to offer and sell up to 9,200,000 ordinary shares from time to time. The agent may receive a commission of up to 3.0% of gross proceeds. Sales depend on company instructions and the agreement’s terms.
Financial metrics and liquidity
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures, and no financial valuation of the subsidiary sale. No cash consideration is due at the sale closing. The ATM program authorizes potential share sales but does not specify how many shares will be sold or the proceeds; actual proceeds and dilution are therefore unclear from this filing.
Changes, outlook, and risks
- The subsidiary sale would transfer ownership of BeyondSpring Ltd. to Biolin, subject to customary closing conditions. The filing does not state that the sale has closed or provide a closing date. It says no regulatory approval is required for closing.
- The China trial work is intended to support BeyondSpring’s global registration strategy, but enrollment performance and trial completion remain important execution conditions.
- BeyondSpring may terminate the collaboration agreement if Bulin fails to meet the enrollment target by the end of the three-year period or takes certain adverse actions affecting the China trial. Both sides also have specified termination rights, including if closing has not occurred by a contractually specified date.
- The ATM agreement may be terminated by either the company or the agent by written notice. Share sales could dilute existing shareholders; the filing does not quantify potential dilution beyond the maximum 9,200,000 shares.
Important facts for investors to verify
- Whether and when the subsidiary sale closes, and the resulting ownership and financial-consolidation effects.
- The enrollment target, progress toward it, and the consequences of any shortfall under the agreement.
- Whether the China trial is completed and its data can be incorporated into the global dataset and support the registration strategy.
- How many ATM shares are ultimately sold, the gross and net proceeds, and the resulting dilution.
- The full agreement terms, including conditions, termination provisions, and any omitted schedules or redacted provisions, in the filed exhibits.